文献速递慢性肾脏病遗传性与小管间质肾病

支持意见:托伐普坦延缓常染色体显性多囊肾病进展

Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

本文为支持托伐普坦治疗常染色体显性多囊肾病(ADPKD)的论述。基于临床前研究及两项大型3期临床试验,托伐普坦可减缓早期肾脏增长及早晚期eGFR下降;单中心长期分析显示其效应持续且累积,支持疾病修饰作用。在获批国家,快速进展的ADPKD患者应被告知治疗选择及获益与风险。

要点

  • 托伐普坦可减缓早期ADPKD肾脏增长及早晚期eGFR下降
  • 单中心长期分析显示效应持续累积,支持疾病修饰作用
  • 用药需教育患者预防排水相关不良事件并警惕肝毒性

核心结论

  • 托伐普坦对快速进展的ADPKD具有疾病修饰作用,在获批国家可考虑用于此类患者。

研究设计与样本

  • 基于体外和体内模型的临床前研究,启动了两项针对ADPKD早期和晚期的大型3期临床试验,设计参考了药代动力学、药效学、短期安全性和耐受性研究。

主要发现

  • 托伐普坦减缓早期ADPKD的肾脏增长,并减缓早期和晚期ADPKD的eGFR下降。
  • 单中心长期结局分析显示,托伐普坦的效应随时间持续且累积。

临床怎么用

  • 在托伐普坦获批的国家,应告知快速进展的ADPKD患者该治疗选择及可能的获益与风险。
  • 决定起始治疗时,处方医生应教育患者预防排水相关不良事件,并警惕和监测托伐普坦潜在肝毒性。

局限性

  • 长期疗效与安全性证据部分来自单中心分析,其他V2受体拮抗剂及联合策略尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

No treatment until now has directly targeted the mechanisms responsible for the development and growth of cysts in autosomal dominant polycystic kidney disease (ADPKD). Strong rationale and preclinical studies using in vitro and in vivo models justified the launching of two large phase 3 clinical trials of tolvaptan in early and later stages of ADPKD. Their design was based on preliminary studies informing on the pharmacokinetics, pharmacodynamics, short-term safety and self-reported tolerability in patients with ADPKD. Tolvaptan slowed kidney growth in the early stage and estimated glomerular filtration rate decline in early and later stages of the disease. All participants had the opportunity to enroll in open-label extension trials to ascertain long-term safety and efficacy. In a single-center analysis of long-term outcomes, the effect of tolvaptan was sustained and cumulative over time supporting a disease-modifying effect of tolvaptan in ADPKD. In the countries where tolvaptan has been approved by regulatory agencies, patients with rapidly progressive ADPKD should be informed about the option of treatment including possible benefits and risks. If a decision to initiate treatment is made, prescribing physicians should educate the patients on the prevention of aquaresis-related adverse events and should be vigilant in the surveillance and management of the potential tolvaptan hepatotoxicity. Other vasopressin V2 receptor antagonists, possibly without potential hepatotoxicity, alternative strategies targeting vasopressin and combination with other drugs able to enhance the efficacy or reduce the aquaresis associated with tolvaptan, deserve further study.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Torres VE. Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2019. PMID: 30312438. doi:10.1093/ndt/gfy297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。